Safety and efficacy of immune checkpoint inhibitors in advanced urological cancers with pre-existing autoimmune disorders: a retrospective international multicenter study

BACKGROUND: There is limited experience regarding the safety and efficacy of checkpoint inhibitors (CPI) in patients with autoimmune disorders (AD) and advanced urological cancers as they are generally excluded from clinical trials due to risk of exacerbations. METHODS: This multicenter retrospectiv...

Full description

Saved in:
Bibliographic Details
Published in:J Immunother Cancer
Main Authors: Martinez Chanza, Nieves, Xie, Wanling, Issa, Majd, Dzimitrowicz, Hannah, Tripathi, Abhishek, Beuselinck, Benoit, Lam, Elaine, Zakharia, Yousef, Mckay, Rana, Shah, Sumit, Mortazavi, Amir, R. Harrison, Michael, Sideris, Spyridon, Kaymakcalan, Marina D, Abou Alaiwi, Sarah, Nassar, Amin H, Nuzzo, Pier Vitale, Hamid, Anis, K Choueiri, Toni, C Harshman, Lauren
Format: Artigo
Language:Inglês
Published: BMJ Publishing Group 2020
Subjects:
Clinical/Translational Cancer Immunotherapy
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7174076/
https://ncbi.nlm.nih.gov/pubmed/32217762
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-000538
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items